P1.08-036 Thoracotomy and VATS-Surgery in Local Non-Small Cell Lung Cancer: Differences in Long-Term Health Related Quality of Life

Abstract

survival rates of p-I-II and IIIA mutant/wild were 96.8%/ 92.1% and 81.6%/61.8% respectively. The median survival time of p-stageIIIA mutant was 80.5 months, and those of others were not reached. The 3-year DFS of p-I-II and IIIA mutant/wild were 78.3%/69.2% and 27.1%/ 45.1%, respectively. There were no significant difference in OS and DFS at each p-stage despite the EGFR mutational status. Compared to the wild type, the p-IIIA mutant group had a poor DFS. Conversely, compared to wild type, the p-I mutant group showed a favorable DFS. According to the subtypes of EGFR mutation, there were no significant differences among EGFR subtypes, but pts with 19del tended to have the worst DFS. In subgroup analysis of 131 pts with recurrence, 3-year survival rate of p-I-II and IIIA mutant/wild were 92.0%/75.8% and 80.8%/45.6% respectively. Pts with p-IIIA mutant showed significantly favorable OS than those of wild type (p¼0.014) as well as with p-I-II wild type. Although OS was not significantly different among the subtypes of EGFR mutation, pts with 19del showed statistically better prognosis than shown by the wild type (p¼0.038). Conclusion: EGFR status was an independent prognostic factor in pts with surgically resected lung adenocarcinoma. Particularly, EGFR exon 19 deletion might be the strongest predictive factor of poor DFS and good OS in resected lung adenocarcinoma.

Evaluation of the effect of video-assisted thoracoscopic surgery on early postoperative pain and quality of life

“…Video-assisted thoracoscopic surgery (VATS) is a minimally invasive approach commonly used in thoracic surgeries for both diagnostic and treatment purposes. VATS is particularly advantageous compared to open methods in terms of pain, complications, and length of hospital stay [1]. This is primarily due to better pulmonary function, activity level, muscle power, and walking capacity.…”